ERBB2 and breast carcinoma: Real-world evidence (RWE) can address these limitations by providing valuable insights into the effectiveness of CDK4/6i in HR+/HER2- a/mBC, particularly for patient subgroups that are frequently underrepresented in breast cancer RCTs, such as elderly and BIPOC populations.